Search results: Sage Journals

Open accessResearch articleFirst published November, 2020

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Bart Van Wijmeersch, Barry A Singer, Aaron Boster [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 1997

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

Franz Fazekas, Florian Deisenhammer, Siegrid Strasser-Fuchs [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 2005

Depression and fatigue in relapsing-remitting MS: the role of symptomatic variability

John J Randolph, Peter A Arnett

Multiple Sclerosis Journal

Restricted accessOtherFirst published September, 2010

Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study

VM Anderson, LK Fisniku, Z. Khaleeli [...]

Multiple Sclerosis Journal

Free accessResearch articleFirst published July, 2016

Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey

Rocco Haase, Jennifer S. Kullmann, Tjalf Ziemssen

Therapeutic Advances in Neurological Disorders

Restricted accessOtherFirst published April, 2008

Avonex Combination Trial in relapsing—remitting MS: rationale,design and baseline data

JA Cohen, PA Calabresi, S. Chakraborty [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published June, 2025

Correlation of Cognition With Disability and Physical Performance in Patients With Relapsing-Remitting MS

Marko Luostarinen, Anne M Portaankorva, Pirjo Urpilainen [...]

Journal of Central Nervous System Disease

Restricted accessResearch articleFirst published January, 1997

Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials

L Truyen, F Barkhof, M Tas [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published December, 2014

Identical lesion morphology in primary progressive and relapsing–remitting MS –an ultrahigh field MRI study

Joseph Kuchling, Caren Ramien, Ivan Bozin [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published July, 2018

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry

Tim Spelman, Thomas Frisell, Fredrik Piehl [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published November, 2020

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Bart Van Wijmeersch, Barry A Singer, Aaron Boster [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 1997

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

Franz Fazekas, Florian Deisenhammer, Siegrid Strasser-Fuchs [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 2005

Depression and fatigue in relapsing-remitting MS: the role of symptomatic variability

John J Randolph, Peter A Arnett

Multiple Sclerosis Journal

Restricted accessOtherFirst published September, 2010

Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study

VM Anderson, LK Fisniku, Z. Khaleeli [...]

Multiple Sclerosis Journal

Free accessResearch articleFirst published July, 2016

Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey

Rocco Haase, Jennifer S. Kullmann, Tjalf Ziemssen

Therapeutic Advances in Neurological Disorders

Restricted accessOtherFirst published April, 2008

Avonex Combination Trial in relapsing—remitting MS: rationale,design and baseline data

JA Cohen, PA Calabresi, S. Chakraborty [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published June, 2025

Correlation of Cognition With Disability and Physical Performance in Patients With Relapsing-Remitting MS

Marko Luostarinen, Anne M Portaankorva, Pirjo Urpilainen [...]

Journal of Central Nervous System Disease

Restricted accessResearch articleFirst published January, 1997

Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials

L Truyen, F Barkhof, M Tas [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published December, 2014

Identical lesion morphology in primary progressive and relapsing–remitting MS –an ultrahigh field MRI study

Joseph Kuchling, Caren Ramien, Ivan Bozin [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published July, 2018

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry

Tim Spelman, Thomas Frisell, Fredrik Piehl [...]

Multiple Sclerosis Journal